Sage Journals: Discover world-class research

Abstract

Background:

Still too little is known about the natural history of clinical outcome measures beyond the Expanded Disability Status Scale (EDSS), such as the timed 25-foot walk (T25FW) and nine-hole peg test (9HPT) in secondary progressive multiple sclerosis (SPMS).

Objective:

To describe progression on the EDSS, T25FW, 9HPT, and their combinations. To investigate the association of the baseline characteristics age, sex, EDSS, T25FW, gadolinium-enhancing lesions, and relapse activity with EDSS and T25FW progression.

Methods:

Using original trial data from the placebo arms of the IMPACT and ASCEND randomized controlled trials, we describe disability progression (with and without 3- or 6-month confirmation). We investigated the association of selected baseline characteristics with EDSS and T25FW progression over 2 years using binary logistic regression.

Results:

T25FW was the single outcome measure with the largest proportion of patients progressing, followed by EDSS and 9HPT. EDSS and T25FW at baseline were associated with EDSS and T25FW progression in both data sets. Age and relapse activity were only mild and inconsistent predictors, while sex and gadolinium enhancement at baseline did not predict disability progression in either data set.

Conclusion:

Our analyses inform the selection of primary outcome measures as well as inclusion criteria for clinical trials in SPMS.

Keywords

Clinical trial outcome measurement progressive

Get full access to this article

View all access options for this article.

References

Reich

Lucchinetti

Calabresi

Multiple sclerosis. N Engl J Med 2018; 378: 169–180.

Thompson

Baranzini

Geurts

, et al. Multiple sclerosis. Lancet Lond Engl 2018; 391: 1622–1636.

Rovaris

Confavreux

Furlan

, et al. Secondary progressive multiple sclerosis: Current knowledge and future challenges. Lancet Neurol 2006; 5: 343–354.

Kremenchutzky

Rice

GPA

Baskerville

, et al. The natural history of multiple sclerosis: A geographically based study 9: Observations on the progressive phase of the disease. Brain 2006; 129(Pt. 3): 584–594.

Scalfari

Neuhaus

Degenhardt

, et al. The natural history of multiple sclerosis: A geographically based study 10: Relapses and long-term disability. Brain 2010; 133(Pt. 7): 1914–1929.

Kapoor

Campbell

, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): A phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol 2018; 17(5): 405–415.

Kappos

Polman

Pozzilli

, et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 2001; 57(11): 1969–1975.

Panitch

Miller

Paty

, et al. Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology 2004; 63(10): 1788–1795.

Kappos

Bar-Or

Cree

BAC

, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet 2018; 391(10127): 1263–1273.

10.

Cohen

Cutter

Fischer

, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59(5): 679–687.

11.

Metz

Liu

W-Q.

Effective treatment of progressive MS remains elusive. Lancet 2018; 391(10127): 1239–1240.

12.

Koch

Cutter

Stys

, et al. Treatment trials in progressive MS—Current challenges and future directions. Nat Rev Neurol 2013; 9(9): 496–503.

13.

Kurtzke

JF.

Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983; 33(11): 1444–1452.

14.

Amato

Fratiglioni

Groppi

, et al. Interrater reliability in assessing functional systems and disability on the Kurtzke Scale in multiple sclerosis. Arch Neurol 1988; 45(7): 746–748.

15.

Noseworthy

Vandervoort

Wong

, et al. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology 1990; 40(6): 971–975.

16.

Ontaneda

LaRocca

Coetzee

, et al.; NMSS MSFC Task Force. Revisiting the multiple sclerosis functional composite: Proceedings from the National Multiple Sclerosis Society (NMSS) task force on clinical disability measures. Mult Scler 2012; 18(8): 1074–1080.

17.

Bosma

Kragt

Brieva

, et al. The search for responsive clinical endpoints in primary progressive multiple sclerosis. Mult Scler 2009; 15(6): 715–720.

18.

van Winsen

Kragt

Hoogervorst

, et al. Outcome measurement in multiple sclerosis: Detection of clinically relevant improvement. Mult Scler 2010; 16(5): 604–610.

19.

Kragt

van der Linden

Nielsen

, et al. Clinical impact of 20% worsening on timed 25-foot walk and 9-hole Peg Test in multiple sclerosis. Mult Scler 2006; 12(5): 594–598.

20.

Bosma

Kragt

Polman

, et al. Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS. Mult Scler 2013; 19(3): 326–333.

21.

Cutter

Baier

Rudick

, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122(Pt. 5): 871–882.

22.

Oxford

Vogel

, et al. Adult norms for a commercially available Nine-Hole Peg Test for finger dexterity. Am J Occup Ther 2003; 57(5): 570–573.

23.

Roxburgh

Seaman

Masterman

, et al. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity. Neurology 2005; 64(7): 1144–1151.

24.

Cohen

Krishnan

Goodman

, et al. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis. JAMA Neurol 2014; 71(11): 1386–1393.

25.

Motl

Cohen

Benedict

, et al. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler 2017; 23(5): 704–710.

26.

Feys

Lamers

Francis

, et al. The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Mult Scler 2017; 23(5): 711–720.

27.

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998; 352: 1491–1497.

28.

Hommes

Sorensen

Fazekas

, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: Randomised placebo-controlled trial. Lancet 2004; 364(9440): 1149–1156.

29.

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 2001; 56(11): 1496–1504.

30.

R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2017.

31.

Goldman

Motl

Scagnelli

, et al. Clinically meaningful performance benchmarks in MS: Timed 25-foot walk and the real world. Neurology 2013; 81(21): 1856–1863.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.64 MB

Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material